$67.76
2.42% yesterday
NYSE, Nov 15, 10:00 pm CET
ISIN
US28176E1082
Symbol
EW

Edwards Lifesciences Target price 2024 - Analyst rating & recommendation

Edwards Lifesciences Classifications & Recommendation:

Buy
42%
Hold
58%

Edwards Lifesciences Price Target

Target Price $74.68
Price $67.76
Potential
Number of Estimates 25
25 Analysts have issued a price target Edwards Lifesciences 2025 . The average Edwards Lifesciences target price is $74.68. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 33 analysts: 14 Analysts recommend Edwards Lifesciences to buy, 19 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Edwards Lifesciences stock has an average upside potential 2025 of . Most analysts recommend the Edwards Lifesciences stock at Hold.

Sales and Margin forecast 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Revenue Billion $ 6.00 5.84
11.56% 2.80%
EBITDA Margin 30.22% 30.32%
12.98% 0.33%
Net Margin 22.59% 24.93%
15.51% 10.35%

28 Analysts have issued a sales forecast Edwards Lifesciences 2024 . The average Edwards Lifesciences sales estimate is

$5.8b
Unlock
. This is
0.62% lower
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$6.0b 1.57%
Unlock
, the lowest is
$5.4b 7.77%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2023 $6.0b 11.56%
2024
$5.8b 2.80%
Unlock
2025
$5.9b 1.23%
Unlock
2026
$6.5b 9.49%
Unlock
2027
$7.2b 11.42%
Unlock
2028
$7.8b 7.57%
Unlock

21 Analysts have issued an Edwards Lifesciences EBITDA forecast 2024. The average Edwards Lifesciences EBITDA estimate is

$1.8b
Unlock
. This is
1.23% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$1.8b 5.45%
Unlock
, the lowest is
$1.6b 7.73%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2023 $1.8b 2.92%
2024
$1.8b 2.49%
Unlock
2025
$1.8b 0.01%
Unlock
2026
$2.0b 13.04%
Unlock
2027
$2.3b 14.24%
Unlock
2028
$2.6b 12.89%
Unlock

EBITDA Margin

2023 30.22% 12.98%
2024
30.32% 0.33%
Unlock
2025
29.95% 1.22%
Unlock
2026
30.92% 3.24%
Unlock
2027
31.71% 2.55%
Unlock
2028
33.27% 4.92%
Unlock

10 Edwards Lifesciences Analysts have issued a net profit forecast 2024. The average Edwards Lifesciences net profit estimate is

$1.5b
Unlock
. This is
64.41% lower
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$2.0b 51.95%
Unlock
, the lowest is
$1.2b 70.56%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2023 $1.4b 5.74%
2024
$1.5b 7.24%
Unlock
2025
$1.4b 3.37%
Unlock
2026
$1.6b 14.02%
Unlock
2027
$1.9b 17.02%
Unlock
2028
$1.7b 7.08%
Unlock

Net Margin

2023 22.59% 15.51%
2024
24.93% 10.35%
Unlock
2025
23.79% 4.57%
Unlock
2026
24.78% 4.16%
Unlock
2027
26.02% 5.00%
Unlock
2028
22.48% 13.60%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Earnings Per Share $ 2.30 2.47
5.74% 7.39%
P/E 27.47
EV/Sales 6.22

10 Analysts have issued a Edwards Lifesciences forecast for earnings per share. The average Edwards Lifesciences <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is

$2.47
Unlock
. This is
64.36% lower
Unlock
than earnings per share in the financial year 2023. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is
$3.33 51.95%
Unlock
, the lowest is
$2.04 70.56%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2023 $2.30 5.74%
2024
$2.47 7.39%
Unlock
2025
$2.38 3.64%
Unlock
2026
$2.72 14.29%
Unlock
2027
$3.18 16.91%
Unlock
2028
$2.96 6.92%
Unlock

P/E ratio

Current 9.77 64.42%
2024
27.47 181.17%
Unlock
2025
28.43 3.49%
Unlock
2026
24.93 12.31%
Unlock
2027
21.31 14.52%
Unlock
2028
22.93 7.60%
Unlock

Based on analysts' sales estimates for 2024, the Edwards Lifesciences stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of

and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 6.18 4.92%
2024
6.22 0.61%
Unlock
2025
6.14 1.22%
Unlock
2026
5.61 8.67%
Unlock
2027
5.03 10.25%
Unlock
2028
4.68 7.04%
Unlock

P/S ratio

Current 6.81 1.69%
2024
6.85 0.62%
Unlock
2025
6.76 1.22%
Unlock
2026
6.18 8.67%
Unlock
2027
5.54 10.25%
Unlock
2028
5.15 7.04%
Unlock

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today